Fluoxetine Inhibits Multidrug Resistance Extrusion Pumps and Enhances Responses to Chemotherapy in Syngeneic and in Human Xenograft Mouse Tumor Models
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Multidrug resistance (MDR) operated by extrusion pumps such as P-glycoprotein and multidrug-resistance-associated-proteins, is a major reason for poor responses and failures in cancer chemotherapy. MDR modulators (chemosensitizers) were found among drugs approved for noncancer indications and their derivatives. Yet toxicity, adverse effects, and poor solubility at doses required for MDR reversal prevent their clinical application. Among newly designed chemosensitizers, some still suffer from toxicity and adverse effects, whereas others progressed to clinical trials. Diversities among tumors and among MDR pumps indicate a need for several clinically approved MDR modulators. Here we report for the first time that fluoxetine (Prozac), the well-known antidepressant, is a highly effective chemosensitizer. In vitro, fluoxetine enhanced (10- to 100-fold) cytotoxicity of anticancer drugs (doxorubicin, mitomycin C, vinblastine, and paclitaxel) in drug-resistant but not in drug-sensitive cells (5 and 3 lines, respectively). Fluoxetine increased drug accumulation within MDR-cells and inhibited drug efflux from those cells. In vivo, fluoxetine enhanced doxorubicin accumulation within tumors (12-fold) with unaltered pharmacokinetics. In four resistant mouse tumor models of both syngeneic and human xenograft, combination treatment of fluoxetine and doxorubicin generated substantial (P < 0.001) improvements in tumor responses and in survivals (2- to 3-fold). Moreover, fluoxetine reversed MDR at doses that are well below its human safety limits, free of the severe dose-related toxicity, adverse effects, and poor solubility that are obstacles to other chemosensitizers. This low-dose range, together with the findings reported here, indicate that fluoxetine has a high potential to join the arsenal of MDR reversal agents that may reach the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536 · cited 3×
“The eight cell lines used in this study fall into three categories: (1) drug-sensitive: HT29 (human colon carcinoma), P388/WT (murine leukemia), and MCF-7 (human breast carcinoma); (2) inherently resistant (P-glycoprotein): C-26 (Colon carcinoma ref.”
Method
Cited by
VDAC, a multi-functional mitochondrial protein regulating cell life and death
Shoshan-Barmatz, V., De Pinto, V., Zweckstetter, M., Raviv, Z., Keinan, N., & Arbel, N. (2010) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2010.03.002 · Cited by 782
Hyaluronan–CD44 interactions as potential targets for cancer therapy
Misra, S., Heldin, P., Hascall, V. C., Karamanos, N. K., Skandalis, S. S., Markwald, R. R., & Ghatak, S. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2011.08071.x · Cited by 494
Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management
Jin, P., Jiang, J., Zhou, L., Huang, Z., Nice, E. C., Huang, C., & Fu, L. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01313-4 · Cited by 273
Sun, M., Kingdom, J., Baczyk, D., Lye, S. J., Matthews, S. G., & Gibb, W. (2006) · Placenta · doi:10.1016/j.placenta.2005.05.007 · Cited by 223
Nahon, E., Israelson, A., Abu-Hamad, S., & Shoshan-Barmatz, V. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.08.020 · Cited by 101
“Indeed, fluoxetine enhances doxorubicin accumulation within tumors [8].”
Background
Metadata
- Authors
- Peer, D., Dekel, Y., Melikhov, D., & Margalit, R.
- Venue
- Cancer Research
- Published
- 2004-10-15
- Volume
- 64
- Issue
- 20
- Pages
- 7562-7569
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2122126525
- Cited by
- 98
- References
- 1
- FWCI
- 1.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fluoxetine Inhibits Multidrug Resistance Extrusion Pumps and Enhances Responses to Chemotherapy in Syngeneic and in Human Xenograft Mouse Tumor Models. https://app.cochat.ai/papers/10.1158/0008-5472.can-03-4046
- The paper
- Peer, D., Dekel, Y., Melikhov, D., & Margalit, R. (2004). Fluoxetine Inhibits Multidrug Resistance Extrusion Pumps and Enhances Responses to Chemotherapy in Syngeneic and in Human Xenograft Mouse Tumor Models. Cancer Research. https://doi.org/10.1158/0008-5472.can-03-4046
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.